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Abstract
Donor infection or colonization with a multidrug-resistant organism (MDRO) impacts organ 
utilization and recipient antibiotic management. Approaches to identifying donors at risk of 
carrying MDROs are unknown. We sought to determine the risk factors for MDROs among 
transplant donors. A multicenter retrospective cohort study was conducted at four transplant 
centers between 2015 and 2016. All deceased donors who donated at least one organ were 
included. Cultures obtained during the donor’s terminal hospitalization and organ procurement 
were evaluated. The primary outcome was isolation of an MDRO on culture. Multivariable Cox 
regression was used to determine risk factors associated with time to donor MDRO. Of 440 total 
donors, 64 (15%) donors grew an MDRO on culture. Predictors of an MDRO on donor culture 
included: hepatitis C viremia (hazard ratio [HR] 4.09, 95% CI 1.71–9.78, P=0.002), need for 
dialysis (HR 4.59, 95% confidence interval [CI] 1.09–19.21, P=0.037), prior hematopoietic cell 
transplant (HR 7.57, 95% CI 1.03–55.75, P=0.047), and exposure to antibiotics with a narrow 
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gram-negative spectrum (HR 1.13, 95% CI 1.00–1.27, P=0.045). This is the first study to 
determine risk factors for MDROs among deceased donors and will be important for risk 
stratifying potential donors and informing transplant recipient prophylaxis.
1. INTRODUCTION
One of the most significant issues facing solid organ transplantation (SOT) is the limited 
supply of organ donors. Deceased donors with positive bacterial cultures have been utilized 
inconsistently in the past due to prior reports of SOT donors transmitting bacteria to their 
organ recipients via the allograft, causing donor-derived bacterial infections (DDBIs)1–4. 
DDBIs have been linked to poor outcomes including vascular anastomosis dehiscence, 
overwhelming infection, and death1–4.
One area of particular concern is the organ donor who carries a multidrug-resistant organism 
(MDRO), since a DDBI due to an MDRO may be more difficult to treat in the recipient. 
Indeed, there are several case series describing transmission of MDROs from donors to 
recipients with poor attendant outcomes5. Because of this, the current national transplant 
guidelines recommend exercising caution when considering the use of organs that may carry 
an MDRO6. Importantly, however, donor cultures are not uniformly finalized prior to donor 
evaluation, so the presence of an MDRO on donor culture may be discovered after the 
decision about organ use has been made.
The presence of an MDRO on donor culture not only impacts whether an organ is used, but 
may also impact the perioperative antibiotic regimen administered to the recipient7. 
Observational studies have suggested that peri- and post-operative antibiotics for the 
recipient that are active against donor organisms may reduce the risk for DDBIs8,9. Standard 
perioperative prophylaxis regimens for SOT procedures do not target MDROs, however10,11. 
Thus, the ability to identify donors, prior to transplantation, who are at higher risk of 
carrying an MDRO would be crucial for determining the antibiotic regimen for the recipient. 
This would be a preferable strategy to broadening perioperative prophylaxis for all transplant 
recipients, because the antibiotics required to treat MDROs often confer additional toxicities 
and may themselves promote emergence of MDROs.
Though risk factors for MDROs in the general population have been well-studied, there are 
no published studies to our knowledge that have determined risk factors associated with 
MDROs among deceased organ donors specifically. Although all deceased donors are 
admitted to an intensive care unit (ICU) during their terminal hospitalization (a known risk 
factor for MDRO colonization12,13), deceased organ donors are typically younger, with 
fewer medical comorbidities, increased rates of injection drug use (IDU), and increased rates 
of traumatic injuries compared to the general population receiving ICU care14,15. In 
addition, the clinical data available to transplant centers about the organ donor is more 
limited than that available to clinicians when caring for a hospitalized patient directly14. 
Thus, there is a pressing need to determine the donor factors that are (1) associated with 
MDROs and (2) can be determined by transplant centers at the time of donor evaluation, so 
that donors can be risk stratified prior to organ procurement. In this study, we sought to 
identify risk factors associated with MDROs among deceased SOT donors.
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2. MATERIALS AND METHODS
2.1 Study design and setting.
A multicenter retrospective cohort study was performed at four tertiary care transplant 
centers in Philadelphia: the Hospital of the University of Pennsylvania (HUP) (776 beds), 
Temple University Hospital (TUH) (722 beds), Hahnemann University Hospital (HUH) (496 
beds), and Albert Einstein Medical Center (AEMC) (772 beds).
2.2 Study population.
The initial source population included all deceased donors who were evaluated by the local 
organ procurement organization (OPO)—the Gift of Life Donor Program (GLDP)—and 
who ultimately donated at least one organ to a recipient at one of the participating transplant 
centers between January 1, 2015 and July 1, 2016. Eligible donors were identified by the 
GLDP, which evaluates all deceased organ donors in eastern Pennsylvania, southern New 
Jersey, and Delaware. Donors who were imported from outside of the GLDP’s region were 
not included.
2.3 Outcome.
The primary outcome was time to donor MDRO on a bacterial culture that was taken as part 
of clinical care during the donor’s terminal hospitalization (hereafter referred to as a 
“hospital culture”) or at the time of organ procurement (hereafter referred to as an “OPO 
culture”). We included the following organisms in our definition of MDROs: methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus species 
(VRE), extended-spectrum cephalosporin-resistant (ESC-R) Enterobacteriaceae (EB), 
carbapenem-resistant EB (CRE), multidrug-resistant (MDR)-Pseudomonas species, and 
MDR-Acinetobacter species16,17. Cultures from any anatomic site were considered. The 
distinction of infection versus colonization with the MDRO pathogen was not determined 
because (1) this is difficult to determine among organ donors for whom limited clinical data 
are available; (2) donor infection is not routinely differentiated from colonization by 
transplant clinicians when determining which organs to accept and what perioperative 
prophylaxis regimen to administer to the recipient18,19.
Each donor was included as a subject only once. If an MDRO pathogen was isolated on 
multiple occasions in the same patient, only the first episode was considered. The study was 
approved by the Institutional Review Board at each of the participating transplant centers 
(see Supporting Information [A]).
2.4 Data collection.
Data on donors were abstracted from the GLDP medical record system. Information was 
collected on the following: donor demographics (e.g., age, gender, race), comorbidities (e.g., 
diabetes, asthma, hemodialysis, substance use disorders), outpatient medications, IDU, 
procedures performed during the terminal hospitalization, medications administered during 
the terminal hospitalization (including all antibiotics and administration of the T4 
protocol20,21), death mechanism, donor type (donation after circulatory death [DCD] versus 
donation after brain death [DBD]), whether the donor was a standard criteria donor (SCD) or 
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expanded criteria donor (ECD), Public Health Service (PHS)-increased risk status22,23, viral 
serologies (e.g. for hepatitis C virus [HCV]), donor cultures (including the date of culture, 
anatomic site of culture, organism(s) that grew on culture, and the organism’s in vitro 
susceptibilities).
For the purposes of the analysis, antibiotic exposures were grouped into four major 
categories: (1) broad Gram-negative (GN) coverage; (2) narrow GN coverage; (3) broad 
Gram-positive (GP) coverage; and (4) narrow GP coverage (see Supporting Information [B] 
for details of the antibiotic categories). All antibiotics administered to the donors are 
included in one of the antibiotic groups above. Antibiotic exposures were evaluated as both 
binary (any exposure or none) and continuous variables (duration of antibiotic exposures, 
measured in days).
Following the initial analyses using this antibiotic grouping, we performed three sensitivity 
analyses where the definition of “narrow GN antibiotics” was revised (see Supporting 
Information [D.2.] for details).
2.5 Susceptibility testing of bacterial isolates.
Susceptibility testing of donor bacterial isolates was performed at either the donor hospital’s 
microbiology laboratory or the GLDP’s reference laboratory (LabsInc, Denver, CO). The in 
vitro susceptibilities were not able to be confirmed due to the retrospective nature of the 
study and the innumerable different donor hospitals from which the donors originated. The 
in vitro antibiotic susceptibility profile of each organism that grew on hospital or OPO 
cultures was reviewed by an infectious diseases trained physician (J.A.A.) and was used to 
categorize donors as having grown an MDRO pathogen or not. The Centers for Disease 
Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria for 
MDROs was used to define VRE, MRSA, ESC-R EB, CRE, MDR-Pseudomonas, and 
MDR-Acinetobacter17 (see Supporting Information [C] for precise definitions).
2.6 Statistical analysis.
Donors were characterized by potential risk factors, such as demographics, comorbidities, 
death mechanism, and antibiotic exposures during the terminal hospitalization. Continuous 
variables were compared using the Student t-test or Wilcoxon rank-sum test, and categorical 
variables were compared using the χ2 or Fisher exact test. For the adjusted analysis, a 
survival analysis was employed. The primary outcome was time to first donor MDRO. The 
time at risk was measured in days. Time zero was the first day of the donor’s terminal 
hospitalization. The failure event was an MDRO pathogen on culture; the failure date was 
the day on which the culture that grew an MDRO was collected from the donor. MDRO 
colonization status before the terminal admission was unknown. Donors were censored 
when their organs were procured. We ascertained antibiotics administered during the time at 
risk, and these were modeled as time-varying covariates in order to account for both duration 
and patterns of use.
A Kaplan Meier curve was plotted to assess the overall time to donor MDRO in this 
population. To assess whether duration of hospitalization affected the risk for donor 
MDROs, we evaluated a Hazard Estimate Plot, which shows the instantaneous hazard for an 
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MDRO during the terminal hospital. Subsequently, bivariable Cox proportional hazard 
regression was used to examine the relationship between each risk factor and time to 
MDRO. Variables from bivariable analyses with P values <0.20 were considered for 
inclusion in the final multivariable model. Variables were added to the model in order of 
biologic plausibility. Variables were retained in the final model if they had a P value of 
<0.05 in the multivariable Cox model. The proportional hazards assumption was verified. A 
hazard ratio (HR) and 95% confidence interval (CI) were calculated to evaluate the strength 
of any association.
Subgroup analyses were then performed evaluating (1) time to MRSA, and (2) time to ESC-
R EB. These subanalyses were performed to investigate whether the risk factors for the most 
common MDR-GP organism may be different than the risk factors for the most common 
MDR-GN organism. The same statistical approach was used for these subgroup analyses as 
was described for the primary outcome. All analyses were performed using STATA v.14.0 
(StataCorp, College Station, Texas).
3. RESULTS
3.1 Study population.
A total of 440 deceased organ donors gave at least one organ to an SOT recipient at one of 
the four transplant centers during the study period. Of these, 64 (15%) had an MDRO 
pathogen isolated from a hospital or OPO culture.
Among the entire study cohort, the median age was 37 years (interquartile range [IQR] 27–
52), and 183 (41%) were women. Sixty-four (15%) were DCD, 84 (19%) were ECD, and 
150 (34%) met the PHS-increased risk criteria. The most common comorbidities included 
hypertension (124, 28%) and chronic respiratory diseases (e.g. emphysema) (73, 17%). The 
median number of organs donated per donor was 3 (IQR 2–5). The median length of stay for 
the terminal hospitalization was 3 days (IQR 2–5, range 1–84). See Table 1 for additional 
donor baseline characteristics.
3.2 Overview of donor culture results.
Of the 440 donors, 380 (86%) had at least one positive bacterial culture that was obtained 
during the terminal hospitalization or at the time of organ procurement. The median number 
of positive cultures per donor was 2 (IQR 1–3, range 0–8). The most common anatomical 
site of bacterial growth was the respiratory tract, with 337 (76%) donors having a positive 
sputum culture and 127 (29%) having a positive bronchoalveolar lavage (BAL) culture (not 
mutually exclusive). There were fewer positive blood (49, 11%) and urine cultures (70, 
16%). Among OPO cultures, there were 26 (6%) with a positive ureter culture and 37 (8%) 
with a positive perfusate culture.
The most common organism isolated on donor cultures was S. aureus (183, 42% of donors). 
This was followed by Enterobacteriaceae (139, 32% of donors) and Candida species (127, 
29% of donors). The most common MDRO pathogens were MRSA (40, 9% of donors) and 
ESC-R EB (20, 5% of donors). The most common site of MDRO pathogen growth was the 
respiratory tract (53, 12% of donors). There were five donors (1%) who were bacteremic 
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with an MDRO: three with MRSA, one with MDR-Pseudomonas, and one with ESC-R EB. 
There were four donors who grew more than one MDRO species. See Table 2 for additional 
information on the donor culture results.
3.3 Risk factors for MDRO pathogens on donor cultures.
The time to donor MDRO for the entire cohort is shown in the Kaplan Meier failure curve 
(Figure 1). Of note, three donors did not contribute any time at risk because they grew an 
MDRO pathogen on the day of admission. The Kaplan Meier curve shows that 20% of 
donors were colonized with an MDRO by day 10 (95% CI 7–14), and 33% of donors were 
colonized with an MDRO by day 15 (95% CI 10–31).
On multivariable analysis (Table 3), we found that there was an increased hazard of MDRO 
pathogens among donors with HCV viremia (aHR 4.09, 95% CI 1.71–9.78, P=0.002), a 
prior hematopoietic cell transplant (HCT) (aHR 7.57, 95% CI 1.03–55.76, P=0.047), and 
need for dialysis (aHR 4.59, 95% CI 1.09–19.21, P=0.037). We also found that any exposure 
to narrow GN antibiotics during the terminal hospitalization was associated with a 
significantly increased hazard of donor MDROs (aHR 1.13, 1.00–1.27, P=0.045). Further, 
there was a significant association between the duration of narrow GN antibiotics and the 
hazard of donor MDROs (aHR 1.04, 95% CI 1.01–1.07, P=0.018, per day of additional 
exposure) (Supporting Information Table 1). Finally, we also found that donors who had 
tetrahydrocannabinol (THC) detected on their toxicology screen at the time of admission to 
their terminal hospitalization had a borderline increased hazard of MDRO pathogens (aHR 
1.90, 95% CI 0.97–3.73, P=0.061).
3.4 Risk factors for MRSA and ESC-R EB growth on donor cultures.
On multivariable analysis, we found that there was an increased hazard of MRSA among 
donors with HCV viremia (aHR 5.39, 95% CI 2.02–14.36, P=0.001), prior HCT (aHR 
18.95, 95% CI 2.43–147.55, P=0.005), receipt of the T4 protocol (aHR 5.12, 95% CI 1.49–
17.63, P=0.010), and a positive toxicology screen for THC (aHR 2.88, 95% CI 1.33–6.24, 
P=0.007) (Table 4). Any exposure to antibiotics with narrow GP coverage during the 
terminal hospitalization was associated with a reduced hazard of MRSA (aHR 0.80, 95% CI 
0.66–0.98, P=0.032) (Table 4), though the duration of exposure to narrow GP antibiotics was 
not significantly associated with the outcome (data not shown).
Next, we found on multivariable analysis that there was an increased hazard of ESC-R EB 
among donors who died due to asphyxiation (aHR 5.85, 95% CI 1.86–18.39, P=0.003) and 
donors who were exposed to narrow GN antibiotics during their terminal hospitalization 
(aHR 1.17, 95% CI 1.01–1.37, P=0.039) (Table 5). The duration of exposure to narrow GN 
antibiotics was not significantly associated with the outcome (aHR 1.04, 95% CI 0.99–1.09, 
P=0.117, data not shown).
3.5 Sensitivity analyses for antibiotic categorization.
Secondarily, three revised categorizations of the “narrow GN antibiotic” group were 
evaluated, and their association with any donor MDRO and donor ESC-R EB was 
determined. There were no significant associations between the revised versions of narrow 
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GN antibiotics and the outcomes. The results are detailed in the Supporting Information (D.
2.).
4. DISCUSSION
In this multicenter cohort study, we found that deceased donors with HCV viremia, a history 
of dialysis, a history of HCT, and exposure to antibiotics with a narrow GN spectrum during 
their terminal hospitalization were at increased risk for an MDRO. These findings represent 
the first evaluation of risk factors for MDROs among deceased organ donors to date, and 
provide a preliminary framework for a novel, standardized preemptive strategy for (1) risk 
stratification of potential donors and (2) determining a personalized perioperative antibiotic 
prophylaxis regimen for recipients. This would represent a significant innovation over the 
current practice, where donor MDROs are often discovered after transplantation, delaying 
targeted recipient prophylaxis.
The significant association between donor HCV viremia and growth of an MDRO, 
particularly MRSA, is a novel finding that is uniquely important in the deceased donor 
cohort. This association may be related to the direct link between HCV viremia and IDU; it 
has been shown previously that there is a cumulative increase in risk for HCV infection with 
increasing duration of IDU24. IDU in turn is a well-established risk factor for bacterial 
infections, particularly MRSA25–27. Though a history of IDU was captured as a separate 
variable in this study, and was not significantly associated with the outcome, the accuracy of 
the information obtained about IDU is unclear given the reporting by a surrogate and the 
stigma associated with IDU14. Thus, HCV viremia may be an objective measure of IDU 
activity. Active HCV infection is also known to have immunomodulatory effects, as does the 
liver dysfunction associated with long-standing HCV viremia, which may increase the risk 
for MDRO infection28,29. With the current opioid and IDU epidemic in the US, as well as 
the debate in the transplant field about how donors with HCV should be utilized, this is an 
important finding that merits further study; our study would suggest that an unintended 
consequence of HCV-positive donation may include an increased risk of MDRO 
transmission15,30–33.
The association between medical comorbidities—including dialysis and prior HCT—and 
risk of MDROs has been well-established in prior studies of the general population34–38. It 
should be noted that both dialysis and prior HCT were infrequent comorbidities among our 
deceased donor cohort, and thus, further study is required to confirm their significance.
Our study also confirmed an important relationship between exposure to narrow GN 
antibiotics and donor MDROs, particularly ESC-R EB. We found that with each additional 
day of narrow GN antibiotic exposure, there was a 4% increase in the hazard of MDROs. 
This is consistent with prior literature that has shown antibiotic exposures to be a key risk 
factor for the development of MDROs39,40. Notably, however, we also found that any 
exposure to narrow GN antibiotics was associated with an increased risk of donor MDROs, 
suggesting that prolonged antibiotic exposure is not required to promote the emergence of 
MDROs among deceased donors.
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We also found that recent use of THC was associated with a borderline increased risk of any 
MDRO pathogen and a significantly increased risk of MRSA on donor culture. It has been 
previously shown that marijuana smoking can cause chronic respiratory disease and 
pneumonia, which may increase the risk for MDROs including MRSA in the respiratory 
tract41,42. Further, there have been recent reports documenting abundant bacterial (as well as 
fungal) colonization of marijuana, including MDRO pathogens43. Finally, THC has been 
shown previously to have immunomodulatory effects44,45, which could impact the donor’s 
risk for MDRO infection or colonization.
We secondarily performed risk factor analyses for MRSA and ESC-R EB. These subgroup 
analyses were limited by smaller cohorts, but we identified unique risk factors for each. We 
observed (1) an increased risk for MRSA associated with administration of the T4 protocol 
to donors, and (2) a reduced risk for MRSA when donors were administered antibiotics with 
narrow GP activity. The T4 protocol is typically employed as one component of “aggressive 
management of brain-dead donors” which also includes pulmonary artery catheterization, 
intravenous fluid resuscitation, and vasopressor infusions21. Such management may increase 
the risk for bacterial infections, particularly MDROs, due to the extensive central venous 
access required. Further, the administration of high-dose glucocorticoids as part of the T4 
protocol may result in a degree of immune dysfunction that also increases this risk. The 
association between narrow GP antibiotics and a reduced hazard of MRSA likely relates to 
the fact that narrow GP agents are the standard perioperative antibiotics used by the GLDP 
at the time of organ procurement. Thus, narrow GP antibiotics are likely a marker for donors 
who were not previously known to be colonized with MRSA or went to organ procurement 
without the need for additional, broader antibiotics (e.g. due to growing an MDRO 
pathogen).
In the ESC-R EB analysis, we found that there was an increased risk for ESC-R EB among 
donors who died due to asphyxiation. This association may be related to the fact that all 
donors with death from asphyxiation (e.g. drowning, hanging) have hypoxic and 
hypoventilatory respiratory failure and require significant mechanical ventilatory support46; 
respiratory failure and mechanical ventilation are known to increase the risk of respiratory 
colonization and infection with MDR-GNs including ESC-R EB47,48.
There are several potential limitations of our study: (1) Since donor hospital cultures were 
obtained during routine care, donors who did not have infectious symptoms may have had 
fewer bacterial cultures obtained, which may have limited the detection of an MDRO. The 
OPO cultures performed by the GLDP are standardized, however, so every donor had the 
opportunity to have an MDRO detected. Further, any heterogeneity in MDRO surveillance 
practices between hospitals could impact recovery of MDROs, but none of the MDROs that 
contributed to the outcomes in this study were obtained from surveillance cultures. (2) We 
did not capture information about donor travel history and were not able to account for this 
in the evaluation of risk factors for MDROs. (3) “MDRO pathogens” include a variety of 
different organisms which may have different risk factors; the size of the study precluded a 
fully stratified analysis for each organism—or a stratification based on anatomical site of 
MDRO growth—but we were able to evaluate risk factors for MRSA and ESC-R EB 
separately so as to partially address this issue. (4) These data were collected from a single 
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OPO, and the results may not be generalizable to other institutions with dissimilar rates of 
MDROs among deceased donors. (5) The majority of MDROs were grown on respiratory 
tract samples, and there is considerable controversy as to the significance of respiratory tract 
cultures for non-lung recipients. However, we sought to capture both infection and 
colonization with MDROs in this study, and isolation of an MDRO from the respiratory tract 
does signify donor colonization with that MDRO. (6) Because clinical data on deceased 
donors prior to their terminal hospitalization is not available, we are not able to determine 
the proportion of the donors who were colonized with an MDRO prior to their terminal 
hospitalization.
In conclusion, the results of our study provide the first determination of donor factors 
associated with MDRO colonization or infection. We found that 20% of deceased donors are 
colonized with an MDRO by day 10 of their terminal hospitalization. We identified two 
novel risk factors for MDRO pathogens, particularly MRSA, that are uniquely important to 
the deceased donor pool, namely HCV viremia and recent THC use. Although DDBIs are 
uncommon, the potential for adverse outcomes in recipients with MDRO DDBIs is high due 
to delayed administration of appropriate antimicrobials. Moreover, the increasing use of 
expanded criteria donors, including those with HCV, makes it likely that more donors will be 
infected or colonized with an MDRO in the future. Consequently, this first study identifying 
risk factors for donor MDROs may aid in earlier administration of appropriate empiric 
antibiotics for recipients, and will likely be an important tool for improving transplant 
outcomes. Further studies are needed to determine the impact of MDROs on the donor pool, 
the true risk for transmission of such MDROs to SOT recipients, and the impact that 
prophylaxis has on this transmission rate.
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AEMC Albert Einstein Medical Center
BAL Bronchoalveolar lavage
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CRE Carbapenem-resistant Enterobacteriaceae
CDC Centers for Disease Control and Prevention
CLSI Clinical and Laboratory Standards Institute
CI Confidence interval
DBD Donation after brain death
DCD Donation after circulatory death
DDBI Donor-derived bacterial infection
EB Enterobacteriaceae
ECD Expanded criteria donor
ESBL Extended-spectrum beta-lactamase
ESC-R Extended-spectrum cephalosporin-resistant
GLDP Gift of Life Donor Program
GN Gram-negative
GP Gram-positive
HUH Hahnemann University Hospital
HR Hazard ratio
HCT Hematopoietic cell transplant
HCV Hepatitis C virus
HUP Hospital of the University of Pennsylvania
IDU Injection drug use
ICU Intensive care unit
IQR Interquartile range
MRSA Methicillin-resistant Staphylococcus aureus
MDR Multidrug-resistant
MDRO Multidrug-resistant organism
NHSN National Healthcare Safety Network
OPO Organ procurement organization
PHS Public Health Service
SOT Solid organ transplantation
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Spp Species
SCD Standard criteria donor
TUH Temple University Hospital
THC Tetrahydrocannabinol
T4 Thyroxine
VRE Vancomycin-resistant Enterococcus
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Figure 1. Kaplan Meier failure curve of time to donor MDRO.
Time zero is the day of admission to the terminal hospitalization. The failure event is MDRO 
colonization/infection. Donors were censored at the time of organ procurement. Plotted 
through 20 days of follow-up.
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Table 1.
Baseline characteristics of the deceased organ donors stratified by MDRO pathogen status.
Donor characteristica, b No MDRO pathogen (N=376) MDRO pathogen (N=64) P value
Demographics
Age (years) (median, IQR) 39 (27–53) 34 (25–50) 0.064
Female gender 150 (40%) 33 (52%) 0.074
Race/Ethnicity
Black/African American 50 (13%) 9 (14%) 0.171
White/Caucasian 279 (74%) 52 (81%)
Hispanic 38 (10%) 1 (2%)
Other 9 (2%) 2 (3%)
Comorbidities
Chronic kidney disease 8 (2%) 1 (2%) 0.768
Dialysis 4 (1%) 2 (3%) 0.189
Liver disease 3 (1%) 0 (0%) 0.623
Malignancy 11 (3%) 1 (2%) 0.459
Solid organ transplant 3 (1%) 0 (0%) 0.623
Hematopoietic cell transplant 1 (0.3%) 1 (2%) 0.270
Immunomodulator treatmentc 31 (8%) 3 (5%) 0.450
Diabetes mellitus 43 (11%) 9 (13%) 0.795
Donor type
DCD 52 (14%) 12 (19%) 0.294
ECD 73 (19%) 11 (17%) 0.689
PHS-increased risk 128 (34%) 22 (34%) 0.936
Death mechanism
Drug intoxication 80 (21%) 16 (25%) 0.491
Asphyxiation 22 (6%) 5 (8%) 0.538
Cardiovascular 93 (25%) 16 (25%) 0.946
Gunshot wound 25 (7%) 4 (6%) 0.587
Blunt injury 51 (13%) 8 (13%) 0.829
Intracranial hemorrhage 99 (26%) 13 (20%) 0.317
Drug use
THC 42 (11%) 11 (17%) 0.166
Opiates (IDU or non-IDU) 104 (28%) 22 (34%) 0.261
IDU 75 (20%) 17 (27%) 0.237
Serologies and laboratory testing
HCV seropositive 25 (7%) 8 (13%) 0.098
HCV viremia 15 (5%) 6 (10%) 0.083
Procedures during terminal hospitalization
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Donor characteristica, b No MDRO pathogen (N=376) MDRO pathogen (N=64) P value
Tracheostomy 5 (1%) 3 (5%) 0.095
Percutaneous endoscopic gastrostomy 4 (1%) 3 (5%) 0.066
Open abdomen 1 (0.3%) 0 (0%) >0.999
Donor management
Length of stay of terminal hospitalization (days) (median, IQR) 3 (2–5) 4 (3–7) <0.001
T4 protocol 312 (83%) 52 (81%) 0.802
Antibiotics
Any antibiotic 366 (97%) 61 (97%) 0.817
Narrow GPd 301 (80%) 40 (63%) 0.003
Broad GPe 84 (22%) 19 (30%) 0.191
Narrow GNf 36 (10%) 12 (19%) 0.028
Broad GNg 249 (66%) 50 (78%) 0.053
Number of antibiotics per donor (median, IQR) 2 (1–2) 2 (2–3) 0.034
Antibiotic days per donor (median, IQR) 4 (3–7) 2 (0–5) 0.001
Length of antibiotics per donor (days) (median, IQR) 3 (2–4) 1 (0–3) <0.001
a
Data are presented as numbers (percentages) except where noted.
bOnly those variables with a P value <0.20 are included in this table, as well as those of notable biologic importance.
c
Immunomodulators included: abatacept, anakinra, apremilast, azathioprine, cyclophosphamide, cyclosporine, denosumab, hydroxychloroquine, 
methotrexate, mycophenolate, rituximab, secukinumab, sulfasalazine, tocilizumab, tofacitinib, infliximab, adalimumab, certolizumab, golimumab, 
etanercept
dNarrow GP antibiotics included cefazolin and nafcillin.
e
Broad GP antibiotics included vancomycin.
fNarrow GN antibiotics included ceftriaxone, cefotaxime, ampicillin/sulbactam, and amoxicillin/clavulanate.
g
Broad GN antibiotics included antibiotics with anti-pseudomonal coverage (cefepime, ceftazidime, piperacillin-tazobactam, meropenem, 
aztreonam, fluoroquinolones, aminoglycosides).
Abbreviations: DCD, donation after circulatory death; ECD, expanded criteria donor; GN, Gram-negative; GP, Gram-positive; HCV, hepatitis C 
virus; IDU, injection drug use; IQR, interquartile range; MDRO, multidrug-resistant organism; PHS, Public Health Service; THC, 
tetrahydrocannabinol
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Table 2.
Overview of donor culture results.
Overview of donor cultures N (%)a
Donors with a positive hospital or OPO culture 380 (86%)
Donors with a positive OPO culture 322 (73%)
Donors with a positive hospital culture 267 (61%)
Number of positive cultures per donor (median [IQR, range]) 2 (1–3, 0–8)
Organisms on culture, stratified by site of growth
S. aureus Donors with S. aureus on culture 183 (42%)
Blood cultures with S. aureus 8
Respiratory cultures with S. aureus 179
Urine cultures with S. aureus 2
Ureter cultures with S. aureus 2
Perfusate cultures with S. aureus 3
Abdominal collection cultures with S. aureus 1
Bone cultures with S. aureus 1
Candida spp Donors with Candida spp on culture 127 (29%)
Blood cultures with Candida spp 6
Respiratory cultures with Candida spp 110
Pleural cultures with Candida spp 1
Urine cultures with Candida spp 24
Ureter cultures with Candida spp 1
Perfusate cultures with Candida spp 6
Abdominal collection cultures with Candida spp 1
Coagulase-negative staphylococci (CoNS) Donors with CoNS on culture 52 (12%)
Blood cultures with CoNS 17
Respiratory cultures with CoNS 15
Urine cultures with CoNS 2
Ureter cultures with CoNS 7
Perfusate cultures with CoNS 12
Bone culture with CoNS 1
Klebsiella spp Donors with Klebsiella spp on culture 44 (10%)
Blood cultures with Klebsiella spp 2
Respiratory cultures with Klebsiella spp 39
Urine cultures with Klebsiella spp 3
Ureter cultures with Klebsiella spp 1
Perfusate cultures with Klebsiella spp 2
Haemophilus influenzae Donors with H. influenzae on culture 43 (10%)
Respiratory cultures with H. influenzae 43
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Overview of donor cultures N (%)a
E. coli Donors with E. coli on culture 38 (9%)
Blood cultures with E. coli 2
Respiratory cultures with E. coli 16
Urine cultures with E. coli 21
Ureter cultures with E. coli 6
Perfusate cultures with E. coli 4
Enterobacter spp Donors with Enterobacter spp on culture 28 (6%)
Respiratory cultures with Enterobacter spp 22
Urine cultures with Enterobacter spp 4
Ureter cultures with Enterobacter spp 2
Perfusate cultures with Enterobacter spp 2
Enterococcus spp Donors with Enterococcus spp on culture 25 (6%)
Respiratory cultures with Enterococcus spp 5
Urine cultures with Enterococcus spp 11
Ureter cultures with Enterococcus spp 7
Perfusate cultures with Enterococcus spp 2
Chest wound cultures with Enterococcus spp 1
Group C and G streptococci Donors with Group C/G streptococci on culture 23 (5%)
Respiratory cultures with Group C/G streptococci 22
Urine cultures with Group C/G streptococci 1
Pseudomonas spp Donors with Pseudomonas spp on culture 22 (5%)
Blood cultures with Pseudomonas spp 1
Respiratory cultures with Pseudomonas spp 21
Urine cultures with Pseudomonas spp 1
MDRO pathogens on culture, stratified by site of growth
MRSA Donors with MRSA on culture 40 (9%)
Blood cultures with MRSA 3
Respiratory cultures with MRSA 38
Urine cultures with MRSA 1
ESC-R Enterobacteriaceae (EB) Donors with ESC-R EB on culture 20 (5%)
Blood cultures with ESC-R EB 1
Respiratory cultures with ESC-R EB 13
Urine cultures with ESC-R EB 4
Ureter cultures with ESC-R EB 1
Perfusate cultures with ESC-R EB 1
VRE Donors with VRE on culture 4 (1%)
Respiratory cultures with VRE 1
Ureter cultures with VRE 2
Perfusate cultures with VRE 1
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Overview of donor cultures N (%)a
Chest wound cultures with VRE 1
MDR-Pseudomonasb Donors with MDR-Pseudomonas on culture 2 (0.5%)
Blood cultures with MDR- Pseudomonas 1
Respiratory cultures with MDR- Pseudomonas 2
CRE Donors with CRE on culture 1 (0.2%)
Respiratory cultures with CRE 1
MDR-Acinetobacterb Donors with MDR-Acinetobacter on culture 1 (0.2%)
Respiratory cultures with MDR-Acinetobacter 1
a
Data are presented as numbers (percentages) except where noted. The denominator for all percentages is the total number of donors. These events 
are not mutually exclusive; each donor may have had multiple positive cultures or multiple organisms on a single culture.
b
The full susceptibility patterns for the three MDR-Pseudomonas isolates and single MDR-Acinetobacter isolate are given in Supporting 
Information (C).
Abbreviations: BAL, bronchoalveolar lavage; CRE, carbapenem-resistant Enterobacteriaceae; ESC-R, extended-spectrum cephalosporin-resistant; 
IQR, interquartile range; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant S. aureus; OPO, organ procurement organization; spp, 
species; VRE, vancomycin-resistant enterococci
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Table 3.
Bivariable and multivariable Cox proportional hazard regression model of time to donor MDRO.
Donor characteristic Bivariable analysis Multivariable analysisb
HR 95% CI P value aHR 95% CI P value
HCV viremia 3.71 1.56–8.82 0.003 4.09 1.71–9.78 0.002
Dialysis 3.50 0.85–14.44 0.084 4.59 1.09–19.21 0.037
Stem cell transplant 5.66 0.78–41.22 0.087 7.57 1.03–55.76 0.047
THC 1.75 0.90–3.40 0.099 1.90 0.97–3.73 0.061
Narrow GN antibioticsa - - - 1.13 1.003–1.27 0.045
aAntibiotic exposure incorporated as a time-varying covariate in the multivariable analysis. There is no bivariable HR estimate for time-varying 
covariates.
b
Proportional hazards test P=0.998
Abbreviations: aHR, adjusted hazard ratio; GN, Gram-negative; HCV, hepatitis C virus; THC, tetrahydrocannabinol
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Table 4.
Bivariable and multivariable Cox proportional hazard regression model of time to MRSA on donor culture.
Donor characteristic Bivariable analysis Multivariable analysisb
HR 95% CI P value aHR 95% CI P value
HCV viremia 5.04 1.91–13.30 0.001 5.39 2.02–14.36 0.001
Stem cell transplant 8.97 1.21–66.33 0.032 18.95 2.43–147.55 0.005
T4 protocol 3.95 1.17–13.31 0.027 5.12 1.49–17.63 0.010
THC 2.53 1.18–5.43 0.017 2.88 1.33–6.24 0.007
Narrow GP antibioticsa - - - 0.80 0.66–0.98 0.032
aAntibiotic exposure incorporated as a time-varying covariate in the multivariable analysis. There is no bivariable HR estimate for time-varying 
covariates.
b
Proportional hazards test P=0.944
Abbreviations: GP, Gram-positive; HCV, hepatitis C virus; THC, tetrahydrocannabinol
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Table 5.
Bivariable and multivariable Cox proportional hazard regression model of time to ESC-R EB on donor culture.
Donor characteristic Bivariable analysis Multivariable analysisb
HR 95% CI P value aHR 95% CI P value
Death from asphyxiation 5.67 1.81–17.82 0.003 5.85 1.86–18.39 0.003
Narrow GN antibioticsa - - - 1.17 1.01–1.37 0.039
aAntibiotic exposure incorporated as a time-varying covariate in the multivariable analysis. There is no bivariable HR estimate for time-varying 
covariates.
b
Proportional hazards test P=0.679
Abbreviations: GN, Gram-negative
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